Abbott (ABT) Gets Japanese MHLW Approval for Next-Gen XIENCE PRIME Stent

Abbott (NYSE: ABT) has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which uses the same drug and biocompatible polymer as the XIENCE V® Everolimus Eluting Coronary Stent System, features an enhanced stent design and a delivery system designed for greater flexibility, ideal radial strength, excellent longitudinal strength and more accurate stent placement. With this approval in Japan, XIENCE PRIME is available in all of the major markets worldwide, including the United States, Europe, China, India and other countries in the Asia-Pacific and Latin America regions.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Abbott Labs (ABT) PT Raised to $135 at TD Cowen
• CoVolt Power files for proposed IPO
• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris